Compounds > temozolomide
Page last updated: 2024-08-16

temozolomide and abemaciclib

temozolomide has been researched along with abemaciclib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Ajamie, RT; De Dios, A; Gelbert, LM; Kulanthaivel, P; Raub, TJ; Sanchez-Martinez, C; Sawada, GA; Shannon, HE; Staton, BA; Wishart, GN1
Cao, Y; Kong, S; Li, X; Qi, Y; Shang, S1
Alshareef, M; Cachia, D; Das, A; Henderson, FC; Infinger, LK; Kanginakudru, I; Lindhorst, SM; Patel, SJ; Porto, GBF; Vandergrift, WA; Varma, AK1

Other Studies

3 other study(ies) available for temozolomide and abemaciclib

ArticleYear
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:9

    Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain; Brain Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dacarbazine; Dogs; Female; Glioblastoma; Madin Darby Canine Kidney Cells; Male; Mice; Piperazines; Protein Kinase Inhibitors; Pyridines; Rats; Temozolomide; Xenograft Model Antitumor Assays

2015
CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:9

    Topics: Aminopyridines; Animals; Apoptosis; Benzimidazoles; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma Protein; Spheroids, Cellular; Temozolomide; Up-Regulation; Xenograft Model Antitumor Assays

2020
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:3

    Topics: Aminopyridines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Benzimidazoles; Brain Neoplasms; Cell Cycle; Cell Survival; Cells, Cultured; Cyclin D; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Guanine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neurons; Phosphatidylinositol 3-Kinases; Pyrazoles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Smad Proteins; Temozolomide; Tumor Suppressor Proteins

2021